GRS

TRANSLATE

MENU menu

Close close menu

GRS Blog

PAST POSTS menu

Close close menu

Out-Of-Specification (OOS) Result Handling Continues as Dominant Theme in FDA Warning Letters

20/6/2011

Giving adequate attention to out-of-specification (OOS) results in batch release decision making and investigation follow up continues as the dominant theme in 2011 in GMP warning letters issued to foreign companies by FDA’s drug and biologic compliance offices.  More ...

 

Author: Greer Deal, Director of Global Regulatory Services (GRS)

Past Posts...

Stem Cells and Autism
18 September 2011